This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Dec 13;8(2):66.

doi: 10.1038/nrendo.2011.230.

Neuroendocrinology: Improved progression-free survival with everolimus plus octreotide in carcinoid syndrome

PMID: 22158198
DOI: 10.1038/nrendo.2011.230

Comment

Neuroendocrinology: Improved progression-free survival with everolimus plus octreotide in carcinoid syndrome

Linda Koch. Nat Rev Endocrinol. 2011.

. 2011 Dec 13;8(2):66.

doi: 10.1038/nrendo.2011.230.

Author

PMID: 22158198
DOI: 10.1038/nrendo.2011.230

No abstract available

PubMed Disclaimer

Comment on

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Pavel ME, et al. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. Lancet. 2011. PMID: 22119496 Clinical Trial.

References

1. Lancet. 2011 Dec 10;378(9808):2005-2012 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.